WASHINGTON, D.C. — Federal regulators are moving to reduce the use of animal testing in drug development, issuing new guidance to help drugmakers adopt alternative methods that rely on human-based data.
What This Means for You
- Future drugs may be developed using human-based testing instead of animals
- New methods could speed up approvals and improve safety predictions
- Drug companies must meet new standards to use these alternatives
The U.S. Food and Drug Administration released draft guidance outlining how drug developers can validate “new approach methodologies,” or NAMs, as substitutes for traditional animal testing.
NAMs refer to scientific testing methods that use human cells, computer modeling, or laboratory systems to evaluate how drugs may affect people, rather than relying on animal studies.
How the New Guidance Works
Under current regulations, drug companies must provide safety data from laboratory testing before beginning clinical trials in humans. Historically, that testing has relied heavily on animals.
The new guidance allows developers to submit data from NAMs, provided the methods are scientifically reliable and appropriate for regulatory decisions.
“This draft guidance advances our commitment to replace animal testing with human-relevant, scientifically rigorous methods,” said Health and Human Services Secretary Robert F. Kennedy Jr.
Key Standards for New Testing Methods
The FDA outlined four principles companies must meet when using NAMs:
- Clearly define how the method will be used in regulatory decisions
- Demonstrate relevance to human biology and toxicity
- Show the method produces consistent and reliable results
- Ensure the approach is appropriate for its intended purpose
Officials said developers are encouraged to consult with FDA reviewers when considering these methods for specific diseases or drug types.
Examples of Alternative Methods
NAMs can include laboratory studies using human cells, three-dimensional models that mimic organs, and computer simulations that predict how drugs behave in the body.
Some approaches also use simpler organisms, such as zebrafish, to study biological effects.
FDA officials said these methods can improve the ability to predict how drugs will perform in humans and identify potential safety risks earlier in development.
“Technological advances are allowing us to move beyond animal testing in drug development,” said FDA Commissioner Marty Makary.
Next Steps
The draft guidance is open for public comment before it is finalized. The FDA said it will continue working with drug developers to expand the use of alternative testing methods and reduce reliance on animal studies.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.